SEARCH RESULTS FOR: 得克萨斯A(525 results)

Export results
Filters
Sort By
10
Results Per Page
10
Results/Pg
Company Name Brand Name GMDN Term Name GMDN Term Status FDA Product Code Name FDA Product Code Device Packaged As Sterile Sterilization Prior To Use Issuing Agency Device Size Device Size Type Device Class Implantable

Show Filters

N/A - 00763000400903

LIT 33TH40L DYSTONIA EMANUALS EN
MEDTRONIC, INC.
33TH40L
In Commercial Distribution

  • 00763000400903 ()


  • Deep brain electrical stimulation system

N/A - 00763000400897

LIT 33TH39L DYSTONIA EMANUALS EN
MEDTRONIC, INC.
33TH39L
In Commercial Distribution

  • 00763000400897 ()


  • Deep brain electrical stimulation system

N/A - 00763000400880

LIT 33TH37L DYSTONIA EMANUALS EN
MEDTRONIC, INC.
33TH37L
In Commercial Distribution

  • 00763000400880 ()


  • Deep brain electrical stimulation system

N/A - 00763000400873

LIT 3330L DYSTONIA EMANUALS EN
MEDTRONIC, INC.
3330L
In Commercial Distribution

  • 00763000400873 ()


  • Deep brain electrical stimulation system

N/A - 00763000400866

LIT 3320L DYSTONIA EMANUALS EN
MEDTRONIC, INC.
3320L
In Commercial Distribution

  • 00763000400866 ()


  • Deep brain electrical stimulation system

Lixelle - 14993478020232

The Lixelle(r) beta 2-microglobulin apheresis column is indicated for the treatment of patients with clinically-diagnosed dialysis-related amyloidosis (DRA).
KANEKA CORPORATION
S-35
Not in Commercial Distribution

  • 24993478020239 ()
  • 14993478020232 ()
  • 04993478010045 ()
N/A

  • Haemoperfusion system absorption column

Lixelle - 14993478020225

The Lixelle(r) beta 2-microglobulin apheresis column is indicated for the treatment of patients with clinically-diagnosed dialysis-related amyloidosis (DRA).
KANEKA CORPORATION
S-25
Not in Commercial Distribution

  • 24993478020222 ()
  • 14993478020225 ()
  • 04993478010069 ()
N/A

  • Haemoperfusion system absorption column

Lixelle - 14993478020218

The Lixelle(r) beta 2-microglobulin apheresis column is indicated for the treatment of patients with clinically-diagnosed dialysis-related amyloidosis (DRA).
KANEKA CORPORATION
S-15
Not in Commercial Distribution

  • 14993478020218 ()
  • 04993478010052 ()
  • 24993478020215 ()
N/A

  • Haemoperfusion system absorption column

LIXELLE - 14993478010066

The Lixelle(r) beta 2-microglobulin apheresis column is indicated for the treatment of patients with clinically-diagnosed dialysis-related amyloidosis (DRA).
KANEKA CORPORATION
S-25
In Commercial Distribution

  • 04993478010069 ()
  • 14993478010066 ()
  • 24993478010063 ()
N/A

  • Haemoperfusion system absorption column

LIXELLE - 14993478010059

The Lixelle(r) beta 2-microglobulin apheresis column is indicated for the treatment of patients with clinically-diagnosed dialysis-related amyloidosis (DRA).
KANEKA CORPORATION
S-15
In Commercial Distribution

  • 04993478010052 ()
  • 14993478010059 ()
  • 24993478010056 ()
N/A

  • Haemoperfusion system absorption column
< 1 2 3 4 5 ... 53 >